I-Mab and MorphoSys to Test C5aR1 Antibody in the US
September 18, 2020 at 05:15 AM EDT
Shanghai 's I-Mab and MorphoSys AG of Munich announced they have permission to start US trials of an anti-C5aR1 antibody in patients with advanced solid tumors. The candidate is designed to be used together with checkpoint inhibitors. Two years ago, I-Mab in-licensed greater China rights to the novel antibody in a $105 million agreement. As part of the deal, I-Mab agreed to conduct ex-China trials of the candidate in return for a single-digit royalty on sales outside of China . More details.... Stock Symbols: (NSDQ: IMAB) (FSE: MOR) Share this with colleagues: // //